Bioquell Dividends - BQE

Bioquell Dividends - BQE

Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Bioquell BQE London Ordinary Share GB0004992003 ORD 10P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  0.00 0.0% 597.00 0.00 0.00 0.00 597.00 01:00:00
more quote information »

Bioquell BQE Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
18/03/2015FinalGBX3.331/12/201331/12/201404/06/201505/06/201502/07/20153.3
18/03/2014FinalGBX3.331/12/201231/12/201304/06/201406/06/201402/07/20143.3
19/03/2013FinalGBX3.0631/12/201131/12/201205/06/201307/06/201301/07/20133.06
20/03/2012FinalGBX2.8331/12/201031/12/201106/06/201208/06/201202/07/20122.83
15/03/2011FinalGBX2.6231/12/200931/12/201001/06/201103/06/201101/07/20112.62
16/03/2010FinalGBX2.4231/12/200831/12/200902/06/201004/06/201001/07/20102.42
24/03/2009FinalGBX2.231/12/200731/12/200810/06/200912/06/200903/07/20092.2

Top Dividend Posts

DateSubject
30/11/2018
12:07
18bt: Price is good, but now I need to find another growth company with an undervalued share price. Perhaps ST will help again.
03/9/2018
08:57
bountyhunter: A quick look at the results shows that "most of its revenues are generated from overseas customers" and "Bioquell's products and services are sold by wholly-owned Bioquell organisations in the UK, USA, France, Germany, Ireland, Singapore, China and through a network of international distributors" so BQE is not too dependent on UK NHS or private hospitals fortunately. Also it's encouraging that "with respect to profitability, the Board believes that the Company will exceed current market expectations for profit for the full year" so that may be driving the share price growth right now. I'll need to look into the details further but no time right now unfortunately! To find my FTSE thread just type FTSE into the EPIC code box at the top right of the page and you should find it (since no one is likely to check UKX).
02/9/2018
18:25
bountyhunter: Looking back at the recent BQE results I am now thinking that the share price strength of late may be simply building on those "bug busting" results: Https://www.investorschronicle.co.uk/comment/2018/08/08/bug-busting-results/
23/8/2018
08:50
countless: I am surprised this has bounced back as I cannot see how their expected turnover justifies the share price. I thought I would share the full email as I found it hard to fully understand without getting the books out to help!
20/8/2018
07:30
bountyhunter: Clearly charting signals cannot be relied upon or if it was that easy we would all be very rich. In my experience some of the time they are right and some of the time they are wrong but there is a better chance of a signal being correct when the market cap is larger and there is more liquidity, although even then it wouldn't be wise to rely on charting signals alone, imho. Re EPS growth LSE gives 794% as the most recent figure which is almost identical to the ADVFN figure. Https://www.londonstockexchange.com/exchange/prices/stocks/summary/fundamentals.html?fourWayKey=GB0004992003GBGBXSSQ3 Of course it would be difficult to maintain such a high figure this year and I'm not expecting or suggesting that but it may account for the share price rise since financials were reported.
26/7/2017
07:37
bountyhunter: The half-yearly report out this morning looks pretty good to me... Financial highlights -- Total revenues including defence sales increased by 19% to GBP14.3 million (2016: GBP12.1 million); up 10% at constant currency rates. -- Bio-decontamination revenues increased by 27% to GBP14.0 million (2016: GBP11.1 million); up 17% at constant currency rates. -- Non-UK revenues amounted to GBP11.3 million (2016: GBP9.0 million) - 79% of total revenues (2016: 75%) -- Gross margin increased to 52% (2016: 46%) -- EBITDA increased 56% to GBP2.5 million (2016: GBP1.6 million) -- Profit before tax more than trebled to GBP1.4 million (2016: GBP0.4 million) -- Basic earnings per share were 5.5p (2016: 0.8p) -- Net cash of GBP11.8 million at 30 June 2017 (2016: GBP7.3 million) Ian Johnson, Chairman of Bioquell PLC, said: "I am pleased to report that after a number of years of little growth, total revenues increased by 19% in the half year and that our core bio-decontamination division produced strong revenue growth of 27%. Profitability improved as a result of a significant improvement in margins coupled with tight cost control. Management continues to seek ways to simplify and focus the business around the core bio-decontamination products and services driving higher margin sales and yielding higher quality earnings. Given the momentum in the business the Board believes that the Company's profit before taxation for the current financial year will exceed current market expectations" Http://uk.advfn.com/stock-market/london/bioquell-BQE/share-news/Bioquell-PLC-Half-year-Report/75307841
06/4/2017
12:19
bountyhunter: Bed & ISA @148.4p - a good move by the FD... Http://uk.advfn.com/stock-market/london/bioquell-BQE/share-news/Bioquell-PLC-Director-PDMR-Shareholding/74281718
13/3/2017
12:35
bountyhunter: buybacks to continue Http://uk.advfn.com/stock-market/london/bioquell-BQE/share-news/Bioquell-PLC-Statement-re-Share-Buyback/74075729
24/8/2016
10:47
bangalorebob: Bioquell's EBITDA increased 14% to £1.6 million in the six months to the end of June and the group has now terminated its strategic review. Overall revenues declined by 3% to £12.1 million (2015: £12.5 million) but bio-decontamination revenues (excluding defence sales) rose by 8% to £11.1 million (2015: £10.3 million) and non-UK revenues amounted to £9.0 million (2015: £10.0 million) - representing 74% of total revenues. Gross margin increased to 46% (2015: 42%). Earnings per share were 0.8p (2015: 82.5p, 0.2p excluding the profit on disposal of TRaC). Following the completion of the June tender offer, £40.8 million of cash was returned to shareholders via a share buyback, leaving net cash of £7.3 million at 30 June, 2016 (2015: £47.7 million). Chairman Ian Johnson said: "Whilst overall revenues declined slightly as a result of lower defence sales compared with the first half of 2015, I am pleased to report that our bio-decontamination business grew by 8%. "Profitability improved as a result of our cost reduction programme - and management continues to seek further improvements in the financial performance of the business through greater focus on the international Life Sciences market and driving up the proportion of recurring revenues. "The board has now concluded the strategic review announced in 2015 and believes that Bioquell shareholders' interests would best be served by continuing to build a world class bio-decontamination business and focusing on further improving its financial performance. "Accordingly the management of the business will be restructured. I have become Executive Chairman and the current Chief Executive, Nick Adams, has stepped down. In addition, Jay LeCoque has joined the board of Bioquell in the new role of Commercial Director. "On behalf of all Bioquell shareholders I would like to thank Nigel Keen for his seven years as chairman. "I would also like to thank Nick Adams for his substantial contribution as chief executive. Under his leadership Bioquell has changed beyond all recognition from a low technology manufacturer of safety cabinets to a leader in specialist bio-decontamination. "The board is confident that the improved financial performance seen in the first half of the year will carry through to the full year." At 8:17am: (LON:BQE) Bioquell PLC share price was -8p at 145.5p
09/8/2016
18:37
bountyhunter: and now 3.99% http://uk.advfn.com/stock-market/london/bioquell-BQE/share-news/Martin-MacLeish-Form-8-3-Bioquell-PLC/72174506
Your Recent History
LSE
BQE
Bioquell
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191023 19:16:28